1. Home
  2. LAES vs RDHL Comparison

LAES vs RDHL Comparison

Compare LAES & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEALSQ Corp

LAES

SEALSQ Corp

HOLD

Current Price

$3.01

Market Cap

675.0M

Sector

Technology

ML Signal

HOLD

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$0.84

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAES
RDHL
Founded
2022
2009
Country
Switzerland
Israel
Employees
185
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
675.0M
5.4M
IPO Year
2022
2012

Fundamental Metrics

Financial Performance
Metric
LAES
RDHL
Price
$3.01
$0.84
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
19.9M
145.8K
Earning Date
03-31-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$93.36
$381.91
Revenue Next Year
$43.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.99
$0.71
52 Week High
$8.71
$3.31

Technical Indicators

Market Signals
Indicator
LAES
RDHL
Relative Strength Index (RSI) 44.80 41.48
Support Level $2.94 $0.76
Resistance Level $3.40 $0.89
Average True Range (ATR) 0.26 0.07
MACD -0.02 -0.00
Stochastic Oscillator 21.88 19.77

Price Performance

Historical Comparison
LAES
RDHL

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Share on Social Networks: